CompletedNCT00784953Updated Nov 10, 2015

Real Life Effectiveness in Patients With Not Optimally Controlled Asthma

An observational study in Asthma, sponsored by AstraZeneca. Completed at 6 sites in Taiwan. Per ClinicalTrials.gov, last updated 2015-11-10.

Sponsored by AstraZeneca · Observational

Study type: Observational
Time perspective: Prospective
Enrollment: 842
Sex: All

Study summary

A non-interventional study to explore actual asthma control status in real-life environment and to observe the efficacy after stepped-up to Symbicort SMART or various identical regimens.

The study will be implemented by screening asthmatic patients from respiratory clinics to identify those not optimally controlled and required stepping up the controllers to initiate, or to titrate dose of, ICS/LABA including Symbicort.

Conditions studied

Asthma

Browse trials for

Asthma 3,921

Keywords

Symbicort SMART
budesonide
formoterol
ICS/LABA
Asthma Control Questionnaire
Not optimally controlled asthma

In context

Asthma

3,921 studies on the registry are indexed under Asthma; 507 are open to participants now.

This study's enrollment of 842 is above the median of 150 across 970 observational studies indexed under Asthma.

Browse Asthma studies →

Lead sponsor

AstraZeneca is the lead sponsor of 3,429 studies on the registry; 270 are open to participants now.

Of its 357 completed or terminated interventional studies of FDA-regulated products, 173 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

Who can participate

Ages eligible: Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible: All
Accepts healthy volunteers: No
Sampling method: Probability sample

Study population

Medical center

Inclusion criteria

Asthma patient who was partly controlled or uncontrolled by previous controllers of ICS only, or low dose ICS plus either LABA, leukotriene modifier or theophylline; or ICS- naïve with severe and persist symptom based on physician's judgment
According to GINA guideline, who need to step up the controller medications, and ICS/LABA to be prescribed based on physician's discretion

Exclusion criteria

Exclusion Criteria:

Patients aged not within limitation refer to label information of various product prescribed
Patients who have taken oral corticosteroids within 4 weeks prior to enrollment
Patients with contraindications to prescribed medication

Study design

Time perspective: Prospective
Enrollment: 842 participants (actual)

Groups and cohorts

1
Asthma patients who were partly controlled or uncontrolled, need to step up, or adjust dose of the controller medications to ICS/LABA

What researchers measure

Primary outcomes

Change in ACQ score from baseline to the mean of all available data from the follow up visits
Time frame: wk 4±1; wk 12~16

Secondary outcomes

Change in the individual asthma control status & pulmonary function from enrollment
Time frame: wk 4±1; wk 12~16
Dose/usage of ICS/LABA and relievers & Patient compliance
Time frame: wk 4±1; wk 12~16
Medical resource utilization
Time frame: wk 4±1; wk 12~16; 6 month; 12 month

Study locations

6 sites

Research Site
Changhua, Taiwan
Research Site
Kaohsiung, Taiwan
Research Site
Keelung, Taiwan
Research Site
Taichung, Taiwan
Research Site
Tainan, Taiwan
Research Site
Taipei, Taiwan

References and documents

Publications

Cheng SL, Ho ML, Lai YF, Wang HC, Hsu JY, Liu SF, Huang MS, Lee CH, Lin CH, Hang LW, Liu YC, Yang KY, Wang JH. Budesonide/Formoterol Anti-Inflammatory Reliever and Maintenance or Fluticasone Propionate/Salmeterol Plus As-Needed, Short-Acting beta2 Agonist: Real-World Effectiveness in pAtients without Optimally Controlled asThma (REACT) Study. Drug Des Devel Ther. 2020 Dec 8;14:5441-5450. doi: 10.2147/DDDT.S266177. eCollection 2020. Erratum In: Drug Des Devel Ther. 2021 Feb 12;15:515-516. doi: 10.2147/DDDT.S300704. PubMed 33324041 ↗

Updates

Tracking since Sep 25, 2026

No changes since tracking began. The registry record was last updated on Nov 10, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗

Registry details

Key details

Study ID: NCT00784953
Lead sponsor: AstraZeneca
Responsible party: Sponsor
First posted: Nov 4, 2008
Start date: Oct 2008
Primary completion: May 2011
Completion: May 2011
Last update: Nov 10, 2015

Study contacts

Robin Meng, MD, PhD

study director · AstraZeneca Taiwan

Jia-Horng Wang, MD

principal investigator · Taipei Veterans General Hospital, Taiwan

Oversight

Data monitoring committee: No

View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Asthma→

Other studies from this sponsor

AstraZeneca

Start the discussion